MedPath

The effect of insulin detemir on energy balance, postprandial nutrient handling, body fat distribution,and adipose tissue metabolism and gene expression in patients with type 2 diabetes. - Metabolic Effects of Detemir

Phase 1
Conditions
Type 2 Diabetes Mellitus
MedDRA version: 9.1 Level: LLT Classification code 10053247 Term: Insulin-requiring type 2 diabetes mellitus
Registration Number
EUCTR2007-003085-17-GB
Lead Sponsor
niversity of Surrey
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
Not specified
Target Recruitment
30
Inclusion Criteria

1. Informed consent
2. Type 2 diabetes mellitus
3. Treated with metformin
4. Already on treatment with twice-daily NPH insulin with or without short-acting insulin or a 'basal-bolus' regimen
5. Above 18 years of age
6. BMI 27-35
7. Able and willing to perform own blood glucose monitoring
8. Able and willing to maintain consistent eating habits throughout the entire study period
9. Able and willing to maintain consistent physical activity throughout the entire study period.

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1. Patients on sulphonylureas or thiazolidinediones
2. Proliferative retinopathy that has required acute treatment in the last 6 months
3. Impaired hepatic or renal function
4. Cardiac problems
5. Uncontrolled hypertension
6. Mental incapacity, unwillingness or a language barrier precluding adequate understanding or co-operation
7. Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures.

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
Âİ Copyright 2025. All Rights Reserved by MedPath